Tonyco
:
I looked into these guys briefly. They have 3 months of cash runway, NDA violations, court battle with former CEO and another company (Syneos).. Their alcohol detox product hasn't begun clinical trials, so we have no idea how effective it is or quickly it works, or how safe it is. Their more promising product is the MS neuroprotectant, which allows for oral injestion and doesn't lower immune system strength like current best options. Also may repair damage too. Sadly only just finished phase 1, regarding its safety for humans. Sounds like a company with great workers and ideas with bad management.
browny_440
OP
:
so how come over 100 comments of mine have been deleted when I talk positively about this stock across 4 different platforms x youtube ect
browny_440
OP
:
why would a 20yr best drink company in the world all of a sudden leave to a falling company the world is ran by a hand full of people and Coca-Cola theirs one in their somewhere
LooseSpeculator
browny_440
OP
:
Maybe, but not around this reverse split. Get out and rebuy later on the dip. Watch to see if shorts short or down even more after the split. This is not the time to be holding this stock. I will not be buying back in anytime soon but that's just me. Not financial advice, just my own opinion of what I will NOT be doing.
$FSD Pharma (HUGE.US)$ lot of shorts might turn on a short covering
5
Report
browny_440
:
not with all the news that has come out they have a cure for ms and the company that just signed up with them has just released the next big drink
LooseSpeculator
browny_440
:
That is not true. Lately it's when the company is so beaten down in price that it has no other choice. and very bad for shareholders, sorry.
ADMA Biologics Reports Strong Second Quarter 2024 Financial Results and Strategic Business Updates. ADMA Biologics, Inc. (Nasdaq: ADMA), a commercial biopharmaceutical company specializing in manufacturing and marketing specialty biologics, has announced its financial results for the second quarter of 2024. The company reported growth in revenue, net income, and adjusted EBITDA, reflecting the robustness of its operations a...
Oragenics Inc. and Their Recent Announcement on ONP-002. Oragenics Inc. (NYSE: OGEN) recently made a major announcement regarding their lead candidate for concussion treatment, ONP-002. On Thursday, the company revealed that ONP-002 had successfully cleared the FDA-required cardiotoxicity testing. The announcement signals progress toward addressing a unmet medical need in the management and treatment of concussions....
no volume
such a massive win
they have created a cure for MS too
ADMA Biologics, Inc. (Nasdaq: ADMA), a commercial biopharmaceutical company specializing in manufacturing and marketing specialty biologics, has announced its financial results for the second quarter of 2024. The company reported growth in revenue, net income, and adjusted EBITDA, reflecting the robustness of its operations a...
Oragenics Inc. (NYSE: OGEN) recently made a major announcement regarding their lead candidate for concussion treatment, ONP-002. On Thursday, the company revealed that ONP-002 had successfully cleared the FDA-required cardiotoxicity testing. The announcement signals progress toward addressing a unmet medical need in the management and treatment of concussions....
No comment yet